Tumor biomarkers used in combination with existing clinical predictors of recurrence such as Gleason score, stage, and preoperative PSA level [12,13] have been shown to provide additional information for accurately differentiating aggressive and indolent PCa patients [14]. This evidence concerns the gene KLK3 and posterior cortical atrophy.